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Abstract
The synaptic a1b2c2 GABAA receptor is activated phasically by presynaptically
released GABA. The receptor is considered to be inactive between synaptic
events when exposed to ambient GABA because of its low resting affinity to
the transmitter. We tested the hypothesis that a combination of physiological
and/or clinical positive allosteric modulators of the GABAA receptor with
ambient GABA generates measurable steady-state activity. Recombinant
a1b2c2L GABAA receptors were expressed in Xenopus oocytes and activated
by combinations of low concentrations of orthosteric (GABA, taurine) and
allosteric (the steroid allopregnanolone, the anesthetic propofol) agonists, in
the absence and presence of the inhibitory steroid pregnenolone sulfate.
Steady-state activity was analyzed using the three-state cyclic Resting-ActiveDesensitized model. We estimate that the steady-state open probability of the
synaptic a1b2c2L GABAA receptor in the presence of ambient GABA
(1 lmol/L), taurine (10 lmol/L), and physiological levels of allopregnanolone
(0.01 lmol/L) and pregnenolone sulfate (0.1 lmol/L) is 0.008. Coapplication
of a clinical concentration of propofol (1 lmol/L) increases the steady-state
open probability to 0.03. Comparison of total charge transfer for phasic and
tonic activity indicates that steady-state activity can contribute strongly (~20
to >99%) to integrated activity from the synaptic GABAA receptor.

doi: 10.14814/phy2.14230
Physiol Rep, 7 (18), 2019, e14230,
https://doi.org/10.14814/phy2.14230

Introduction
The a1b2c2 GABAA receptors in the central nervous system are concentrated in the postsynaptic membrane.
Upon the release of GABA from the presynaptic nerve terminal, the concentration of the transmitter in the synaptic
cleft rapidly rises to millimolar concentrations (Grabauskas 2005; Scimemi and Beato 2009), activating the vast
majority of the receptors in the postsynaptic membrane.
The synaptic event is terminated by the removal of the
transmitter by transporters and diffusion, followed by
deactivation of the GABAA receptor. The concentration of

ambient GABA between synaptic events is near 1 lmol/L
(Lerma et al. 1986), to which the synaptic receptors are
considered to be unresponsive due to their low resting
affinity to the transmitter (Li and Akk 2015; Shin et al.
2017). Under physiological conditions, the receptor is also
tonically exposed to the endogenous sulfonic acid taurine,
and a number of potentiating (e.g., allopregnanolone) and
inhibitory (e.g., pregnenolone sulfate) neurosteroids.
Coapplication of an allosteric agonist, for example,
propofol or a neuroactive steroid, increases the current
response to a low concentration of GABA. The effect
manifests both as an augmented peak response and
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elevated steady-state current amplitude (Li and Akk 2015;
Germann et al. 2019). We previously showed that in
human embryonic kidney cells expressing a1b2c2L
GABAA receptors, the combination of clinical concentrations of propofol or etomidate with submicromolar concentrations of GABA generates steady-state currents that
are up to 10% of the peak response to saturating GABA.
We inferred that such a potentiation of tonically activated
synaptic-type receptors contributes to the mechanisms of
action of intravenous anesthetics on the GABAA receptor
(Li and Akk 2015).
The goal of the present study was to quantitatively
describe steady-state activity of the a1b2c2L GABAA
receptor in the presence of GABA, taurine, major endogenous neurosteroids, and the anesthetic propofol. Quantitative analyses and predictions of receptor activity were
made in the framework of the three-state cyclic RestingActive-Desensitized model (termed: the RAD model;
Fig. 1) (Germann et al. 2019). The data indicate that the
steady-state open probability (POpen,S.S.) of the synaptictype a1b2c2L receptor is ~0.008 under control conditions,
that is, when exposed to ambient (1 lmol/L) GABA, and
physiological levels of taurine (10 lmol/L), and the steroids allopregnanolone (3a5aP; 10 nmol/L) and pregnenolone sulfate (PS; 0.1 lmol/L). Exposure to clinical
concentrations (0.3–1 lmol/L) of propofol enhanced the
POpen,S.S. by 2–4 fold. The findings are discussed in the
context of total charge transfer during phasic and tonic
transmission by the synaptic GABAA receptor.

Materials and Methods
Receptors and expression
The GABAA receptors were expressed in oocytes harvested
from the African clawed frog (Xenopus laevis). The frogs
were purchased from Xenopus 1 (Dexter, MI). Harvesting
of oocytes was conducted under the Guide for the Care
and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. The animal
protocol was approved by the Animal Studies Committee
of Washington University in St. Louis (Approval No.
20170071).
The receptors consisted of rat a1b2c2L subunits. The
cDNAs in the pcDNA3 vector were linearized with XbaI
(NEB Labs, Ipswich, MA), and the cRNAs were generated
using mMessage mMachine (Ambion, Austin, TX). The
oocytes were injected with a total of 3.5 ng cRNA in a
1:1:5 (a:b:c) ratio. Following injection, the oocytes were
kept in bath solution (96 mmol/L NaCl, 2 mmol/L KCl,
1.8 mmol/L CaCl2, 1 mmol/L MgCl2, 5 mmol/L HEPES;
pH 7.4) with supplements (2.5 mmol/L Na pyruvate, 100
U/mL penicillin, 100 lg/mL streptomycin, 50 lg/mL
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Figure 1. Resting-Active-Desensitized (RAD) model. The kinetic
scheme is shown with two binding sites for agonist X. The receptor
can occupy a resting (R), active (A), or desensitized (D) state. The
active and desensitized states have high affinity to the agonist while
the resting state has low affinity to the agonist. The parameter L (=R/
A) describes the equilibrium between the resting and active states,
and the parameter Q (=A/D) describes the equilibrium between the
active and desensitized states. The parameter KX is the equilibrium
dissociation constant for X in the resting receptor. The parameter
cXKX is the equilibrium dissociation constant for X in the active
receptor, and the parameter dXcXKX is the equilibrium dissociation
constant for X in the desensitized receptor.

gentamycin) at 16°C for 1–2 days prior to conducting
electrophysiological recordings.

Electrophysiology
The electrophysiological experiments were conducted at
room temperature using two-electrode voltage clamp. The
oocytes were placed in the recording chamber (RC-1Z,
Warner Instruments, Hamden, CT) and clamped at
60 mV. Solutions were gravity-applied, at a rate of 5–
8 mL/min, from 30-mL glass syringes with glass luer slips
via Teflon tubing. Solutions were switched manually.
The currents were amplified with an Axoclamp 900A
(Molecular Devices, Sunnyvale, CA) or OC-725C amplifier (Warner Instruments, Hamden, CT), digitized with a
Digidata 1320 or 1200 series digitizer (Molecular
Devices), and stored on a PC using pClamp (Molecular
Devices).
Drug applications to measure steady-state activity
lasted for 60–330 sec (1–5.5 min). Each cell was also
tested with a brief application of 1 mmol/L
GABA + 50 lmol/L propofol that was considered to generate a peak response with open probability (POpen,Peak)
indistinguishable from 1 (Shin et al. 2017).

Data analysis
The current traces were analyzed using Clampfit (Molecular Devices) to determine the peak and steady-state
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amplitudes. In cases where the current response had not
reached steady-state by the end of the agonist application
(DI > 2% during the last 20 sec of agonist application),
steady-state current was estimated by exponential fitting
of the current decay.
The conversion of raw current amplitudes to units of
open probability has been described previously in detail
(Forman and Stewart 2012; Eaton et al. 2016). In brief,
the peak and steady-state responses were matched against
a scale ranging from POpen of 0 (in the absence of
GABAergic agents) to 1 (peak response in the presence of
1 mmol/L GABA + 50 lmol/L propofol in the same cell).
Curve fitting was done using Origin (OriginLab,
Northampton, MA). Data are presented as mean  SD.

Predictions for current responses
The predictions for peak current responses were made as
described in detail previously (Shin et al. 2019). In brief,
the POpen,Peak was calculated using the state function that
pertains to the two-state MWC model (Forman 2012;
Steinbach and Akk 2019). The activation parameters (receptor affinity and efficacy) were taken from earlier studies (Shin et al. 2017; Akk et al. 2018; Shin et al. 2018).
The predictions for steady-state open probability were
made using equation 1 (see below) that pertains to the
three-state model that incorporates a desensitized state
(Fig. 1). In both models, the potentiating effect resulting
from coapplying two or more agonists results from each
agonist independently and additively contributing free
energy toward stabilizing the active state.
When predicting responses to two or more agonists,
the nominal concentration of each agonist was adjusted
to account for cell-to-cell variability (Shin et al. 2019). By
matching the experimental peak response to the previously determined concentration-response relationship, the
predicted response to a combination of agonists is based
on the observed POpen of responses to individual agonists
rather than the nominal concentrations of the individual
agonists. In other words, the predicted response to, for
example, GABA + propofol is calculated based on the
observed responses to GABA and propofol applied separately, rather than on the nominal concentrations of
GABA and propofol.

Steady-State Activation of the Synaptic GABAA Receptor

pH-adjusted, and diluted as needed. Propofol was purchased from MP Biomedicals (Solon, OH). The stock
solution of propofol was made in DMSO at 200 mmol/L
and stored at room temperature. The steroid 3a5aP was
bought from Sigma-Aldrich or Tocris (Bio-Techne, Minneapolis, MN), dissolved in DMSO at 10–20 mmol/L and
stored at room temperature.

Results
Basic description of the three-state model
The electrophysiological data were analyzed in the framework of the three-state Resting-Active-Desensitized (RAD;
Fig. 1) model. In this model, receptor behavior is
described by six parameters. The constants L and Q are
intrinsic to the receptor and describe the equilibrium
between resting and active, and active and desensitized
states, respectively. The parameters NX, KX, cX, and dX are
specific to the agonist. NX is the number of binding sites
for agonist X, and KX the equilibrium dissociation constant of the resting receptor to agonist X. The parameters
cX and dX give ratios of the equilibrium dissociation constants; cX is the ratio of the constant for the active receptor relative to that for the resting receptor and dX that of
the desensitized receptor relative to that for the active
receptor. A value of cX or dX < 1 indicates that the affinity is higher (lower dissociation constant) and accordingly
that the binding of X tends to stabilize the A state relative
to R or D relative to A.
The probability of being active in the framework of the
RAD model in the presence of drug X is described by the
following equation:
1
3

2

PA;½X ¼

6
1 þ Q1 4
¼

1þ

1
1þ½X=ðcX KX Þ
1þ½X=ðdX cX KX

7
N X 5 þ L

h

1þ½X=KX
1þ½X=ðcX KX Þ

1
þ LC½X

iNX

(1)

1
QD½X

where for simplicity


C½X

Materials and chemicals
The inorganic salts and HEPES used to prepare the bath
solution were purchased from Sigma-Aldrich (St. Louis,
MO). GABA was purchased from Sigma-Aldrich, solubilized in bath solution at 500 mmol/L, and stored in aliquots at 20°C. Taurine was purchased from SigmaAldrich, solubilized in bath solution at 300 mmol/L,


1 þ ½X=KX NX
¼
1 þ ½X=ðcX KX Þ

(2)

and
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1 þ ½X=ðcX KX Þ NX
¼
1 þ ½X=ðdX cX KX Þ

(3)
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We note that the probability of being in the active state
(PA) is considered to be equal to the experimentally
determined parameter POpen.
As indicated in Figure 1, the same sites are involved in
all actions of X. If cX = 1 then Γ[X] is also 1 (i.e., the
presence of X has no effect on the ratio of R to A states
relative to the ratio in the absence of X), while if dX = 1
then D[X] = 1 (the presence of X does not alter the ratio
of A to D).
For receptors which show minimal desensitization, that
is, D/A ? 0 and Q?∞, equation 1 approaches:
PA;½X ¼

1
1 þ LC½X

(4)

1
1þ

1
N
QdX X

þ LC½X

!

X
QdN
X
X
1 þ QdN
X

(5)

Accordingly, relative desensitization is predicted to be
constant in the presence of saturating concentrations of
all strong agonists or agonist combinations so long as the
values for d are the same.
For two agonists, X and Y, interacting with distinct
sites (e.g., GABA and propofol), equation 1 is modified as
follows:
PA;½X;½Y ¼

1
1 þ QD½X1 D½Y þ LC½X C½Y

(6)

The denominator in equation 6 can be modified to add
more Γ and D terms for additional agonists, as long as
the additional agonists each interact with distinct sites.
When the agonists X and Y bind to the same sites
(e.g., GABA and taurine), there are no longer separate
and multiplicative terms for Γ and D. In this case, the
probability that the receptor is active is:
PA;½X;½Y ¼

1
1 þ QW1½X;½Y þ LX½X;½Y

(7)

where

W½X;½Y ¼

ð1 þ ½X=cX KX þ ½Y=cY KY Þ
ð1 þ ½X=ðdX cX KX Þ þ ½Y=ðdY cY KY ÞÞ

2019 | Vol. 7 | Iss. 18 | e14230
Page 4


X½X;½Y ¼

N
(8)

N
ð1 þ ½X=KX þ ½Y=KY Þ
ð1 þ ½X=ðcX KX Þ þ ½Y=ðcY KY ÞÞ

(9)

In the most general sense, the receptor may be exposed
to a combination of drugs acting at distinct or overlapping sites, with different affinities for the R, A, or D
states. In this case, the overall level of activation would be
described as follows:
PA ¼

1 þ QQ

X

Equation 4 can be used to describe peak currents,
assuming that desensitization develops slowly compared
to development of peak response (Forman 2012; Steinbach and Akk 2019).
For high concentrations of efficacious agonists (cX<<1)
or agonist combinations, the term LΓX in equation 1
becomes very small and PA for steady-state current
approaches Q/(1 + Q):
PA;1 ¼

and

D½X

1
Q
X;Y

W½X;½Y

1
Q
Q
þ L X C½X X;Y X½X½Y
(10)

The product symbols (Π) indicate that the product is
taken over all drugs which bind to unique sites (X) or
pairs of drugs (indicated by X, Y) which bind to the same
overlapping sites, where the individual terms have been
defined earlier.
The relatively simple form of the equation for a complicated combination of agonists and antagonists reflects
the facts that in this model, different drugs do not interact with each other, and that the receptor changes state as
a unit. Accordingly, the net result of the action of the
many possible agents arises simply from the relative
affinities of drugs for particular states of the receptor that
result in stabilization of one state or another.

Activation and desensitization properties of
the recombinant a1b2c2L GABAA receptor
We exposed cells expressing a1b2c2L receptors to 60–
330 sec applications of 0.1–1000 lmol/L GABA. Each cell
was exposed to only 1–3 test concentrations of GABA to
minimize measurement errors resulting from long-duration recordings. For reference response, each cell was also
exposed to 1 mmol/L GABA + 50 lmol/L propofol that
generated a peak response with open probability near 1
(Ruesch et al. 2012; Shin et al. 2017).
The activation parameters (KGABA, cGABA) were determined from the analysis of peak currents from 5 to 8 cells
per agonist concentration using equation 4. With the
number of GABA binding sites constrained to 2 (Amin
and Weiss 1993) and L held at 8000 (Shin et al. 2017),
we estimate a KGABA of 16  3 lmol/L (best-fit parameter  SE of the fit) and a cGABA of 0.0042  0.0003.
These estimates are similar to those reported previously
(Chang and Weiss 1999; Rusch et al. 2004; Shin et al.
2017).
In the second step of analysis, we fitted the concentration-response relationship for steady-state currents from
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the same set of cells to equation 1. The values of KGABA
and cGABA were constrained to those determined in the
analysis of peak responses (16 lmol/L and 0.0042, respectively). NGABA and L were held at 2 and 8000, respectively,
as
described
above.
Curve-fitting
the
concentration-response data yielded a Q (=A/D) of
0.29  0.02. Thus, under steady-state conditions, the
ratio of active to desensitized receptors is ~ 1:3 for the
a1b2c2L receptor. Sample current responses and the
GABA concentration-response data for peak and steadystate currents are shown in Figure 2.
Taurine is an endogenous sulfonic acid that has been
implicated in modulating inhibitory transmission in the

Steady-State Activation of the Synaptic GABAA Receptor

brain (Jia et al. 2008; Kletke et al. 2013). We determined
the activation properties of taurine on the a1b2c2L receptor. Cells expressing the a1b2c2L receptor were exposed
to 0.1–50 mmol/L taurine. The peak amplitudes were
converted to POpen units, and the concentration-response
curves fitted using equation 4. Curve-fitting yielded a
Ktaurine of 5.1  1.2 mmol/L, and a ctaurine of
0.0075  0.0006. The number of binding sites for taurine
was constrained to 2. Sample current traces and the concentration-response relationship are shown in Figure 3.
We measured receptor desensitization in the presence
of 30 mmol/L taurine, which is a saturating concentration. In five cells, the mean POpen of the steady-state

Figure 2. Peak and steady-state activation of the a1b2c2L receptor by GABA. Panel A shows sample current traces for receptors activated by
1, 10, or 100 lmol/L GABA. The dashed lines show the steady-state current levels as determined by exponential fitting of the decay phase.
Panel B shows the concentration-response relationships for peak and steady-state currents. The data points show mean  SD from 5 to 8 cells
per concentration. The curves were fitted with equation 4 (peak data) and 1 (steady-state data). The best-fit parameters for peak currents are:
KGABA = 16  3 lmol/L and cGABA = 0.0042  0.0003. The curve for steady-state currents was fitted using the KGABA and cGABA values
constrained to those obtained in fitting the peak currents. The best-fit value for Q was 0.29  0.02. The value of L was constrained to 8000
(Shin et al. 2017), the number of binding sites for GABA was constrained to 2 (Amin and Weiss 1993), and the value of dGABA was assumed to
be 1 (see text for discussion).

Figure 3. Peak activation of the a1b2c2L receptor by taurine. Panel A shows sample current traces for receptors activated by 0.1 or 10 mmol/L
taurine. Both traces are from the same cell. Panel B shows responses to 30 mmol/L taurine and 1 mmol/L GABA + 50 lmol/L propofol (Popen
~1) from the same cell. Panel C shows the taurine concentration-response relationship for peak currents. The curve was fitted with equation 4,
yielding estimates for Ktaurine of 5.1  1.2 mmol/L and for ctaurine of 0.0075  0.0006. The value of L was constrained to 8000 and the
number of binding sites for taurine was constrained to 2.
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response was 0.21  0.05. The calculated (eq. 5) value of
Q was 0.34  0.14. We infer that receptor desensitization
is fundamentally similar in the presence of GABA and
taurine. We have assumed that dGABA = 1. If this is not
the case, then the value for Q is actually the inherent
value for Q mutiplied by dGABA2.

Inhibition of steady-state current by the
steroid pregnenolone sulfate
We next investigated receptor modulation by the
endogenous steroid PS. Previous work has indicated
that the steroid inhibits steady-state activity by promoting entry to the desensitized state (Akk et al. 2001;
Eisenman et al. 2003; Germann et al. 2019). Receptors
were activated by 1 mmol/L GABA. Once the steadystate current level was reached (typically following a
120–300 sec application), the cell was exposed to
1 mmol/L GABA plus 0.01–5 lmol/L PS. Each cell was
also tested with 1 mmol/L GABA + 50 lmol/L propofol
(Popen ~ 1). Application of PS alone did not result in
any discernable activation, indicating that cPS is very
close to 1.
Exposure to PS reduced the steady-state current level.
Fitting the concentration-response data to the Hill equation yielded an IC50 of 0.25  0.05 lmol/L and a Hill
coefficient of 1.86  0.53. The PS concentration-response data were also analyzed using equation 6. Curvefitting yielded a KPS of 1.9  1.5 lmol/L, and a dPS of
0.11  0.06 with the number of PS binding sites constrained to 1. These are similar to the values (3.5 lmol/L
and 0.054, respectively) reported recently for the concatemeric a1b2c2L GABAA receptor (Germann et al. 2019).
When NPS was held at 2, the fitted KPS was
1.0  0.6 lmol/L, and dPS 0.35  0.07. There was,

however, no improvement in the quality of the fit (not
shown). Sample currents and the PS concentration-response relationship are shown in Figure 4.

Propofol can increase the steady-state
activation of receptors by GABA
For efficacious agonists (or agonist combinations), the
open probability of the peak response is near 1. The value
of Q can then be directly estimated from the relative
steady-state response using equation 5. For receptors activated by 1 mmol/L GABA, the POpen for steady-state current was 0.18  0.09 (n = 5 cells), and the calculated
value of Q 0.24  0.15 (assuming the value of LΓX in eq.
5 approaches 0). This is similar to the value of Q estimated from fitting the concentration-response curve for
steady-state data (0.29).
To determine the effects of allosteric agonists on desensitization, we measured the effects of 3a5aP and propofol
on steady-state current. The experiments were conducted
by first activating the receptors with 1 mmol/L GABA.
Upon reaching the steady-state response, the drug flow
was switched to 1 mmol/L GABA + 1 lmol/L 3a5aP or
1 mmol/L GABA + 10 lmol/L propofol.
When the switch was made to GABA + 3a5aP, the
level of steady-state response remained unaffected. In 5
cells, the steady-state current level following the switch to
GABA + 3a5aP was 100  1% of the current level in the
presence of GABA alone. The lack of discernable change
indicates that the value for d3a5aP is very close to that for
GABA, which we assume is unity. In contrast, a switch
from GABA to GABA + propofol was accompanied by an
increase in steady-state current. The application of propofol increased the steady-state current by 1.51  0.21-fold
(n = 5 cells).

Figure 4. Receptor inhibition by the steroid pregnenolone sulfate. Panel A shows a sample current trace demonstrating the effect of 0.1 and
2 lmol/L pregnenolone sulfate (PS) on steady-state current from receptors activated by 1 mmol/L GABA. Panel B shows the PS concentrationresponse relationship for receptors activated by 1 mmol/L GABA. The data points show mean  SD from 4 to 5 cells per concentration. The
curve was fitted with equation 6, yielding a Q of 0.21  0.02, KPS of 1.9  1.5 lmol/L, and dPS of 0.11  0.06. The number of binding sites
for PS was held at 1 and cPS was assumed to be 1 (see text). The term LΓGABA was constrained to 0.08. The inset more clearly demonstrates
the incomplete block at high concentrations of PS. Fitting the concentration-response data to the Hill equation yielded an IC50 of
0.25  0.05 lmol/L.
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The peak POpen in the presence of 1 mmol/L GABA is
0.91 (Fig. 2) whereas coapplication of propofol with saturating GABA increases the POpen to near unity (Ruesch
et al. 2012; Shin et al. 2017). Hence, coapplication of
propofol is also expected to enhance POpen,S.S.. However,
this mechanism should only produce approximately a
10% increase in steady-state POpen, rather than the 50%
increase observed.
Alternatively, an increase in steady-state current upon
coapplication of propofol with GABA may result from
propofol having higher affinity to the active than desensitized state of the receptor, thereby stabilizing the active
receptor. To explore this possibility, we recorded the concentration-response relationship for propofol-induced
enhancement of steady-state current. A cell was initially
exposed to 1 mmol/L GABA. Once the current response
neared steady-state, 0.05–10 lmol/L propofol was coapplied with GABA. Each cell was exposed to only a single
concentration of propofol.
The propofol-induced changes in steady-state open
probability were analyzed using equation 6. Curve-fitting
of the pooled data from 5 to 7 cells per concentration
gave a KPRO of 1.2  0.4 lmol/L for the active state and
a dPRO (ratio of the equilibrium dissociation constants of
the desensitized and active states) of 1.17  0.01, with
the number of binding sites arbitrarily constrained to 4.
Sample traces and the concentration-response relationship
are provided in Figure 5. We note that the RAD model
explicitly includes the potentiation produced by propofol,
by the inclusion of the ΓPRO term modifying L.
We next tested the effects of the b2(Y143W) and b2
(M286W) mutations on propofol-induced enhancement
of steady-state current. These mutations reduce receptor
activation by propofol likely by modifying propofol interactions with the individual binding sites on the receptor
(Krasowski et al. 1998; Eaton et al. 2015; Shin et al. 2018;
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Szabo et al. 2019). We hypothesized that if these identified propofol interaction sites mediate the observed
increase in POpen,S.S., then the mutations to the b2(Y143)
and b2(M286) residues will reduce the effect.
The application of 10 lmol/L propofol enhanced the
steady-state open probability in the presence of saturating
GABA by 1.15  0.10-fold (n = 7 cells) or 1.16  0.12fold in receptors containing the b2(Y143W) or b2
(M286W) mutation, respectively. This is similar to the
predicted (1.22-fold) potentiation assuming that either bsubunit mutation eliminates two equipotent and equiefficacious binding sites for propofol. We also tested the effect
of propofol on steady-state current in the receptor containing both mutations (b2(Y143W + M286W)). In this
receptor, the current level in the presence of 10 lmol/L
propofol was reduced by 21  12% (n = 5 cells). We do
not have an explanation for why exposure to propofol
reduces steady-state current, although it is known that
propofol also blocks channels (Adodra and Hales 1995;
Ruesch et al. 2012; Shin et al. 2018). The contributions of
increased maximal POpen and possible block make the
quantitative predictions of the effects of the mutations
somewhat uncertain. However, the overall data on
mutated receptors support the idea that the increase in
steady-state POpen in the presence of propofol is mediated
by previously identified sites that are also involved in activation and potentiation. This conclusion is consistent
with the RAD model.

Steady-state current in the presence of
agonist combinations
To test the generality of the RAD model in predicting
steady-state activity and to determine the independence of
actions of orthosteric and allosteric agonists, we recorded
current responses from cells exposed to several agonist

Figure 5. Modulation of steady-state current by propofol. Panel A shows sample current traces for receptors activated by 1 mmol/L GABA and
exposed to 0.2 or 2 lmol/L propofol (PRO). Coapplication of propofol increases the steady-state current level. Panel B shows the propofol
concentration-response relationship for modulation of steady-state open probability in the presence of 1 mmol/L GABA. The data points show
mean  SD from 5 to 7 cells. The curve was fitted with equation 7, yielding a KPRO of 1.2  0.4 lmol/L for the active state and a dPRO (ratio
of the equilibrium dissociation constants of the active and desensitized states) of 1.17  0.01, with the number of binding sites constrained to
4. The fitted value of Q was 0.24  0.01. The term LΓGABA was constrained to 0.08.
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combinations and combinations of concentrations. The
experimentally observed responses were compared with
those predicted using equation 10. We note that in these
experiments, the concentrations of individual agonists were
selected to produce a wide range of steady-state open probability with no regard to physiological levels of the respective ligands. The concentration of GABA ranged from
0.5 lmol/L to 1 mmol/L, propofol from 2 to 10 lmol/L,
3a5aP from 0.1 to 1 lmol/L, and PS from 0.5 to 1 lmol/L.
In all, 14 combinations of drugs and drug concentrations
were tested.
Overall, there is a good agreement between observed and
predicted POpen,S.S. values. A global fit of all 72 data points
to linear regression yielded an R2 of 0.85 (P < 0.0001) with
a regression slope close to 1 (0.76  0.06). The findings are
presented in Figure 6.

Simulations of tonic activation of the
synaptic GABAA receptor
We used equation 10 to generate predictions of synaptic
receptor activity under steady-state conditions, that is, in
the absence of phasic, presynaptic GABA release. The predictions were made assuming that the receptor is exposed
to GABA, taurine, 3a5aP, and PS. Additionally, we simulated the effect of propofol on receptor activity to mimic
exposure during clinical anesthesia. For all predictions,
the concentration of GABA was held at 1 lmol/L (Lerma
et al. 1986), and the concentration of taurine at 10 lmol/

L (Lerma et al. 1986; Molchanova et al. 2004). The concentration of PS was constrained to 0.1 lmol/L (de Peretti and Mappus 1983; Weill-Engerer et al. 2002). The
concentration of 3a5aP varied between 1 nmol/L and
10 lmol/L (this large range was used in order to demonstrate saturation of the steroid concentration-response
relationship). The simulations were made in the absence
of propofol and in the presence of 0.1, 0.3, or 1 lmol/L
propofol (Engdahl et al. 1998; Dawidowicz et al. 2003).
A graphic presentation of steady-state POpen is provided
in Figure 7. The major finding is that coapplication of
propofol strongly increases POpen,S.S.. Exposure to 1 lmol/
L propofol had an almost fourfold effect at physiological
concentrations (0.01–0.1 lmol/L) of 3a5aP (Fig. 7A).
Coapplication of 0.1 lmol/L PS had a relatively minor
effect on POpen,S.S., largely due to its low affinity. A
change in the concentration of 3a5aP had a relatively
small effect on steady-state current. A tenfold increase in
3a5aP concentration, from 0.01 to 0.1 lmol/L, approximately doubled the POpen,S.S., both in the absence and
presence of propofol.

Discussion
While synaptic GABAA receptors are most conspicuously
activated by phasically released GABA from presynaptic
nerve terminals, the receptors are exposed, persistently, to
a number of endogenous agonists such as taurine and
neuroactive steroids. Administration of clinical agents,

Figure 6. Steady-state activation of the a1b2c2L receptor by combinations of agonists. The graph shows the observed and predicted POpen of
steady-state responses in the presence of GABA and various combinations of allopregnanolone (3a5aP), pregnenolone sulfate (PS), and
propofol (PRO). The predicted values were determined using equation 10 modified to reflect the agonistic effects of GABA, 3a5aP, and
propofol, and the effects of PS and propofol on the equilibrium between Active and Desensitized states. The small symbols show data from
individual cells. The large symbols show mean  SD for each agonist combination. The solid line gives the linear fit to all data points
(R2 = 0.85, P < 0.0001). The dashed line shows ideal agreement between predicted and experimental POpen.
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Figure 7. Predicted steady-state and peak currents in the presence of combinations of GABAergic drugs. Panels A and B show steady-state
currents predicted using equation 10. In all simulations, the a1b2c2L receptor was exposed to 1 lmol/L GABA and 10 lmol/L taurine, whereas
the concentration of 3a5aP varied between 0.01 and 0.1 lmol/L (Panel A), or 1 nmol/L and 10 lmol/L (Panel B) to illustrate the full
concentration-response relationship. The simulations were done in the absence of propofol (PRO; black line) or in the presence of 0.1 (red line),
0.3 (green line), or 1 lmol/L propofol (blue line). The effect of coapplication of 0.1 lmol/L PS on steady-state current is shown as dashed lines,
color-coded for the presence of propofol. Panel C shows the predicted peak currents in the presence of 1 lmol/L GABA and 10 lmol/L taurine
combined with 1 nmol/L–10 lmol/L 3a5aP and 0–1 lmol/L propofol.

including GABAergic anxiolytics and sedatives, is also
characterized by relatively long exposure times. This raises
a possibility that continuous exposure to combinations of
orthosteric and/or allosteric agonists leads to meaningful
tonic activation of the synaptic GABAA receptor. The goal
of this study was to quantitatively describe steady-state
activity in the synaptic-type a1b2c2L GABAA receptor.
The receptors were activated by combinations of GABA,
taurine, 3a5aP, PS, and propofol. Analysis and predictions of receptor activity were done in the framework of a
three-state Resting-Active-Desensitized (RAD) model
(Fig. 1; (Germann et al. 2019)). We infer that tonic activity due to exposure to ambient GABA, taurine, and neuroactive steroids contributes significantly to overall
function of the synaptic GABAA receptor.
We began by investigating the desensitization properties of the a1b2c2L receptor. In the RAD model, the
extent of desensitization is determined by the equilibrium
constant between the active and desensitized states (termed Q; Fig. 1). Analysis of peak and steady-state currents
in the presence of GABA yielded an estimate for Q of
0.29, indicating that under steady-state conditions the
ratio of receptors in the active vs. desensitized state is
~1:3. Using equation 5, we estimate that the maximal
open probability for steady-state activity is 0.23 in the
a1b2c2L receptor in the presence of GABA. Coapplication
of 3a5aP with GABA did not significantly modify steadystate current, whereas exposure to PS and propofol
decreased and increased, respectively, the POpen,S.S.. Analysis of these effects using equation 6, in which a change in
POpen,S.S. is mediated by different affinities of the drug to
active and desensitized states, yielded a ratio of equilibrium dissociation constants of active versus desensitized
state of 2.86 for PS and 0.85 for propofol. In contrast to

these allosteric agents, the orthosteric agonist taurine and
allosteric agonist 3a5aP appear to be similar to GABA in
that they have indistinguishable affinities for the active
and desensitized states.
Throughout the analysis we have assumed that GABA
binds with identical affinities to active and desensitized
receptors (i.e., dGABA = 1). This assumption is based on
detailed single-channel analysis of the related nicotinic
acetylcholine receptor for which it was shown that the
transmitter ACh binds with similar affinities to the active
and desensitized states (Sine et al. 1995; Grosman and
Auerbach 2001). Strictly, our data show that the values of
d are the same in the presence of GABA and taurine,
while dPS is less and dPRO is greater than dGABA.
Coapplication of multiple agonists interacting with distinct sites increases the peak response through energetic
additivity where each agonist independently modifies the
effective value of L (Fig. 1; Ruesch et al. 2012; Akk et al.
2018; Shin et al. 2019)). To test whether the principle of
energetic additivity applies to steady-state currents in the
presence of multiple active agents, we compared the
observed POpen,S.S. recorded in the presence of several
agonist combinations and concentrations of individual
agonists with those calculated using equation 10. The data
summarized in Figure 6 indicate that there is a good
agreement between experimental observations and simulations for a wide range of POpen,S.S..
The RAD model is an extension of the initial MWC
model. In the complete RAD model shown in Figure 1
there are three functional states and three affinity states.
However, the essential features of the MWC model are
retained – that the receptor changes state as a unit (so individual subunits of the receptor are all in the same state)
and that all sites are identical. Under these conditions the
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actions of multiple agonists and antagonists all take place at
the level of stabilizing one state or another. This is the most
practically relevant aspect of this class of models: interactions among agents can be described by analyzing the
actions of one agent in the absence of others, and the effects
of combinations predicted without assuming that there are
specific interactions between agents (i.e., that one drug
affects the affinity of another). However, it is clear that the
GABAA receptor and other transmitter-gated channels have
more than one active and more than one desensitized state,
and known drug actions are not included (for example
open channel block). In addition, these models do not
describe the kinetics of activation. The relative success of
the model in describing receptor properties suggests that
the states labelled R, A, and D reflect average energies of
sets of states with same function.
To simulate steady-state activity under physiological
conditions, we assumed that the receptor is exposed to
1 lmol/L GABA (Lerma et al. 1986), 10 lmol/L taurine
(Lerma et al. 1986; Molchanova et al. 2004), and 10–
100 nmol/L 3a5aP (Cheney et al. 1995; Weill-Engerer et al.
2002). The latter can be considered to reflect the net concentration of all species of potentiating steroids, for example, pregnanolone (3a5bP), tetrahydrodeoxycorticosterone
(THDOC) and others, in addition to 3a5aP. The sum concentration of all potentiating steroids species is almost certainly higher than the concentration of 3a5aP employed in
the calculations above. Because the steroids interact with
the same set of sites, the effects are additive in terms of concentrations (Shin et al. 2019). For example, five potentiating steroid species with similar affinities and efficacies
present at 10 nmol/L concentration each, effectively act as
a single potentiating steroid at 50 nmol/L. We also
assumed that the receptors are exposed to 0.1 lmol/L PS
(de Peretti and Mappus 1983; Weill-Engerer et al. 2002).
Again, this reflects the net concentration of all inhibitory
steroids. Finally, we tested the effect of exposure to 0.1–
1 lmol/L propofol (Engdahl et al. 1998; Dawidowicz et al.
2003) on steady-state activity.
Several conclusions can be made from the simulations
(Fig. 7A). First, the a1b2c2L receptor is minimally active
with a POpen,S.S. of ~ 0.007 when exposed to ambient
GABA and taurine, although this is greater than the POpen
in the absence of any agonist (constitutive
POpen = 0.00012; (Shin et al. 2017)). Second, exposure to
endogenous potentiating steroids has a relatively small
effect on receptor activity. The POpen,S.S. ranges from 0.01
to 0.02 when 10–100 nmol/L 3a5aP (or equivalent potentiating steroids) is coapplied with GABA and taurine
(Fig. 7A). Exposure to 0.1 lmol/L PS (or equivalent inhibitory steroids) is essentially without effect on GABAA
receptor activity (dashed lines Fig. 7A–B). Finally, propofol increases POpen,S.S.. For example, in the presence of
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GABA, taurine, 10 nmol/L 3a5aP and 0.1 lmol/L PS,
exposure to 0.3 or 1 lmol/L propofol increases POpen,S.S.
from 0.008 to 0.013 or 0.03, respectively.
To put these POpen,S.S. values in perspective, we compared total charge transfer for phasic and tonic activity at a
single synapse. For a 1 sec time period, the integrated
charge transfer for tonic activity, in units of POpen 9 s, is
0.008, 0.013, and 0.03 in the absence of propofol and in the
presence of 0.3 or 1 lmol/L propofol, respectively. The
POpen 9 s units can be readily converted to more conventional units. For example, by assuming that a synapse contains 100 activatable a1b2c2L receptors, each generating
1 pA current, the charge transfer is 0.8 pA 9 s (0.8 pC) in
the absence of propofol and 1.3 or 3 pA 9 s (1.3 or 3 pC)
in the presence of 0.3 or 1 lmol/L propofol.
For phasic activity, it is considered that during the
peak synaptic response 100% of receptors are active, that
is, POpen,Peak is indistinguishable from 1 (Kitamura et al.
2003; Takahashi et al. 2006; McDougall et al. 2008). The
decay time constants of sIPSCs are 30 msec under control
conditions, and 65 or 90 msec in the presence of 0.3 or
1 lmol/L propofol (Cao et al. 2018). Then, the total
charge transfer for a single sIPSC is 0.03, 0.065, or 0.09
POpen 9 s in the presence of 0, 0.3, or 1 lmol/L propofol, respectively. In SI units, the total charge transferred
during a single sIPSC is 3 pC in the absence of propofol
and 6.5 pC and 9 pC in the presence of 0.3 and 1 lmol/L
propofol, respectively.
These calculations were made on a per synapse basis.
The true relative charge transfer thus depends on the frequency of synaptic events at an average synapse. The
reported total cellular frequency of sIPSCs in various
preparations ranges from ~1 to >10 Hz (Hajos and Mody
1997; Browne et al. 2001; Chakrabarti et al. 2016). With
10–1000 synapses per cell (Ichikawa et al. 1993; Cullen
et al. 2010; Zhao et al. 2016), the estimated frequency of
sIPSCs per synapse thus varies between 0.001 and 1 Hz.
Accordingly, the relative integrated charge transfer may
range from 0.996:0.004 (at 0.001 Hz frequency per
synapse) to 0.21:0.79 (at 1 Hz) for the ratio of tonic to
phasic activity in the presence of ambient GABA and
physiological taurine, 3a5aP, and PS. While exposure to
propofol enhances the POpen,S.S. (Fig. 7) and increases the
decay time constants of sIPSCs (Cao et al. 2018), its relative effects are similar on tonic and phasic activation of
the synaptic-type receptor and, therefore, on the ratios of
relative integrated charge transfer (0.997:0.003 for tonic
vs. phasic in the presence of 1 lmol/L propofol at
0.001 Hz frequency per synapse and 0.25:0.75 at 1 Hz).
These ratios are independent of the assumptions made
in calculating total charge transfer (i.e., 100 channels at
1 pA each), suggest that tonic activation of the synaptic
GABAA receptor is a significant, and under some
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conditions, the major contributor to overall charge transfer. We emphasize that this comparison strictly applies to
synaptically located receptors. A pool of a1-containing
synaptic-type receptors is located outside of the synapse
(Thomas et al. 2005; Kasugai et al. 2010); these receptors
presumably contribute only to tonic activity. Although
the data indicate that phasic activity only partially contributes to overall charge transfer in the synaptic-type
GABAA receptor, the true physiological significance and
role of each type of activity remains to be determined.
For example, it may be expected that the larger conductance associated with phasic synaptic transmission may
have a larger effect on the probability a cell will fire an
action potential when the IPSC is temporally associated
with excitatory input. One implication of this is that
while propofol similarly modifies tonic and phasic activity
in the a1b2c2 receptor, its clinical effects due to a
decreased probability of action potential firing are likely
mediated through phasic transmission.
Lastly, tonic inhibition has been associated with the
a4bd subtype in many brain regions. Our experiments
did not address the relative contributions of a1b2c2L and
a4bd receptors to overall tonic GABAergic activity. However, given that a4bd receptors are constitutively active
(e.g., (Tang et al. 2010)) and have larger open probability
in the presence of submicromolar concentrations of
GABA (e.g., (Eaton et al. 2014)), our data on steady-state
activation of the a1b2c2L receptor corroborate that tonic
inhibition in neurons is largely mediated by the a4bd
rather than the synaptic-type a1b2c2L receptor.
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